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INTRODUCTION
Myelodysplastic syndrome (MDS) is a group of disorder
characterized by peripheral blood cytopenias in the
presence of hypercellular/normocellular bone marrow
with dysplastic features and increased risk of leukemic
transformation.1 Pathogenesis of MDS is poorly
understood. Apart from its clonal nature, immunological
abnormalities and increased apoptosis mediated by
cytokines has also been proposed.1,2 The diagnosis of
MDS is usually made based upon an evaluation of the
bone marrow and peripheral smear in an appropriate
clinical context.3 Certain cytogenetic abnormalities result
in the diagnosis of MDS in patients with otherwise
unexplained refractory cytopenia and no morphologic
evidence of dysplasia.4 The patients are prone to
develop symptomatic anemia, recurrent infections and
bleeding because of cytopenia. The condition can be
broadly classified into primary and secondary,
depending on whether MDS arises de novo or arises as
a result of previous exposure to chemotherapy, ionizing
radiation and various chemicals.5 According to the
United States cancer surveillance program in 2001, the
overall incidence rate for MDS is 3 - 5 per 100,000
annually that increases markedly with age.6 It usually
affects older individuals more than 60 years of age but
MDS has also been reported in pediatric population.7
Specific cytogenetic abnormalities identified by conven-
tional karyotype analysis or Fluorescence In Situ
Hybridization (FISH) analysis have prognostic signifi-
cance for patients with primary MDS and affects
treatment planning.8 Cytogenetic abnormalities are
found in approximately 40 - 50% of primary MDS and
nearly about 80 - 90% in secondary MDS.9 Cytogenetics
is an essential part of International Prognostic Scoring
System (IPSS) published in 1997, but has also been
incorporated in WHO Classification-based Prognostic
Scoring system (WPSS).10 Determination of clonal
abnormality on diagnosis not only predicts the response
to treatment but also its risk of transformation to acute
leukemia. Allogenic bone marrow transplantation is the
only curative treatment for MDS and its outcome also
depends on the cytogenetic abnormality.11 Though a
number of therapeutic agents like lenalidomide,
dasatinib and azacytidine have been proposed to have
good response in patients with specific cytogenetic
abnormality like deletion 5q (del5q) and monosomy/
deletion 7 (-7/del7).12
Few local studies have been published, encompassing
the clinicopathological spectrum of MDS but cytogenetic
abnormalities in MDS have not yet been reported from
our region.13,14
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Objective: To determine the frequency of cytogenetic abnormalities in patients diagnosed as primary myelodysplastic
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-7/del (7q) in 3 cases (4.2%), -Y and complex 5q in 2 cases (2.8%) each, complex trisomy 8, del 11q , inversion 9, trisomy
19 and del 20q were found in 1 case (1.4%) each. Other abnormalities were found in 11 cases (15.5%).
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This study was undertaken to determine the frequency
of cytogenetic abnormalities in patients diagnosed as
primary myelodysplastic syndrome using conventional
karyotyping.
METHODOLOGY
The subjects in this study were consecutive patients
referred to The Aga Khan University Hospital, Karachi
between January 2006 - June 2012. The patients who
fulfilled WHO criteria for MDS were included.
Cytogenetic analysis was conducted at the time of
diagnosis. The patients with an ambiguous diagnosis of
MDS, those who had previously received chemotherapy
or radiotherapy, and those with MDS secondary to a
previous malignancy were excluded from the analysis.
Data was collected using in house questionnaire.
Informed consent was taken before performing the bone
marrow procedure and cytogenetic analysis.
Chromosome identification and karyotype description
was done according to the International System for
Chromosome Nomenclature (ISCN, 1995).15 Bone
marrow cells were cultured for 24 hours in F-10 Nutrient
mixture (Gibco Cat. No. 11550-035) together with fetal
bovine serum. After 24-hour incubation, 75 ul of
colcemid was added and incubated for 30 minutes at
37°C. The cells were then treated with hypotonic
KCl (0.075 M) for 12 - 15 minutes and fixed with
methanol/acetic acid (3:1). Metaphase chromosomes
were banded using the conventional GTG banding
technique and karyotyped according to the International
System for Human Cytogenetic Nomenclature (ISCN)
1995. At least twenty metaphases were analyzed. A
karyotype was considered simple if there was
involvement of one chromosome, double if two
chromosomes and complex if there was an involvement
of three or more chromosomes.6
Statistical Package for Social Sciences (SPSS) version
19 was used for statistical analysis. Data was presented
as frequencies and percentages.
RESULTS
A total of 122 patients were diagnosed as primary
myelodysplastic syndrome. Out of them, 71 patients had
their karyotype done at the time of diagnosis.
Out of these 71 patients, 42 were males (59.2%) and 29
were females (40.8%). The median age was 60 ± 20
years. Only one patient was under 15 years of age.
Moreover, out of the 71 patients, 37 (52.1%) were
classified as refractory cytopenia with multilineage
dysplasia (RCMD), 17(23.9%) as refractory anemia with
excess blast-II (RAEB-II), 8 (11.3%) as refractory
anemia with excess blast-I (RAEB-I), 6 (8.5%) as
refractory anemia (RA), 2 (2.8%) as refractory anemia
with ringed sideroblast (RARS) and 1 (1.4%) as
refractory cytopenias with multilineage dysplasia-ringed
sideroblast (RCMD-RS) (Table I).
Among 71 patients, 41 (57.7%) showed normal
karyotype and 30 (42.3%) showed clonal karyotypic
abnormalities at diagnosis. Out of which 14 (19.7%) had
single, 11 (15.5%) had complex and 6 (8.5%) had double
cytogenetic abnormalities. The highest number of
chromosomal abnormalities were found in RAEB-II i.e.
10 (58.8%) followed by RAEB-I, n=4 (50%). The
frequency of the different chromosomal abnormalities
and their relationship to the WHO classification is shown
in Table II.
The common abnormalities found were trisomy 8 in 7
cases (9.9%), -7/del (7q) in 3 cases (4.2%), -Y and
complex 5q in 2 cases (2.8%) each, complex trisomy 8,
del 11q , inversion 9, trisomy 19 and del 20q were found
in 1 case (1.4%) each and other abnormalities in 11
cases (15.5%). The latter included various trans-
locations, hyperdiploidy, hypotetraploidy, additions and
monosomies.
DISCUSSION
Myelodysplastic syndrome consist of group of clonal
hematological disorder characterized by peripheral
blood cytopenias in the presence of hypercellular bone
marrow with features of dysplasia. The degree of
dysplasia, cytopenia, number of blast cells and need for
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Table I: Patient clinical characteristics (n=71).
Age
Median (range) in years 60 (10-85)
Sex
Male 42 (59.2%)
Female 29 (40.8%)
Hemoglobin (gm/dl)
< 10 60 (84.5%)
> 10 11 (15.5%)
Absolute neutrophil count  (x109/L)
> 1.8 38 (53.5%)
< 1.8 33 (46.5%)
Platelet count (x109/L)
< 100 49 (69%)
> 100 22 (31%)
Marrow blast cell percentage (%)
< 5 49 (69%)
5-10 13 (18.3%)
11-20 8 (11.3%)
21-30 1 (1.4%)
Cytopenias
Two 30 (42.3%)
Three 22 (31%)
One 18 (25.4%)
None 1 (1.4%)
Morphology
RCMD 37 (52%)
RAEB-II 17 (23.9%)
RAEB-I 8 (11.3%)
RA 6 (8.5%)
RARS 2 (2.8%)
RCMD-RS 1 (1.4%)
Cytogenetic abnormalities
Normal 41 (57.7%)
Abnormal 30 (42.3%) 
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blood transfusions predict the outcome of myelo-
dysplastic syndrome but are prone to subjective
variation. In such cases, the cytogenetic studies form the
mainstay of evaluating the prognosis, treatment and
leukemic transformation. Cytogenetic abnormality can
be carried out by conventional karyotyping or by FISH
analysis both are sensitive for detecting the cytogenetic
abnormality.16,17
In this study, which consisted of 71 patients with de novo
MDS, the male to female ratio of 1.5:1 is consistent with
the well-known male predominance which has been
reported from other Asian and European regions. The
median age was 59 years as found previously in
Pakistani MDS patients14, compared to 63 years in
Chinese, 60 years in Tunisians,18 42 years in Indians19
and 67 years in USA20 and other Western population.
RCMD was most commonly reported WHO classified
entity followed by RAEB-II in this study, comparable to
that reported from Pakistan and China.13,21 Clonal
cytogenetic abnormalities were identified in 30 patients
(42.3%), which was lower than 54.5% in India,19 67.5%
in China,21 higher than Greece (26%) but comparable
with 45% in USA.20
Single chromosomal abnormality was found in 19.2%
followed by complex cytogenetics in 16.4%. Patients
with RAEB-II had highest number of chromosomal
abnormalities i.e. 58.8% comparable to that reported
from India19,21 and USA.19 In China, patients with MDS -
Unclassifiable have the most number of chromosomal
abnormalities.22
In contrast with del5q which is the most reported
cytogenetic abnormality in India,19 Arab Emirates18 and
USA,20 trisomy 8 was found to be most common in this
study population followed by the complex cytogenetics.
The difference could not be clearly explained due to
small sample size and availability of the cytogenetic
studies in this study.
Two patients showed loss of Y-chromosome which is
associated with neutral or favourable survival response.23
A number of novel translocations in MDS have been
reported in literature by various authors24 but in this
study, some other translocations were found in isolation
and as a part of complex karyotype namely t (8;12),
t (6;10), t (1;19) and t (1;11). To the best of authors’
knowledge and literature searched, these translocations
are not yet been reported.
Clinico-haematological characteristics of MDS has been
defined locally by Ehsan et al. and Irfan et al.,13,14 but
this is the first study encompassing the most compre-
hensive cytogenetic characterization.
Karyotypic abnormalities have an essential role in the
diagnosis and determination of prognosis of MDS.
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Table II: Cytogenetic profile of patients with MDS (n=71).
WHO subtype Total cases Normal karyotype (%) Abnormal karyotype (%) Chromosomal abnormalities Number of cases
RCMD 37 23 (62) 14 (37.8) • del 7 • 1
• complex5q • 1
• t(8;12) (q24.3;q15) • 1
• +19 • 1
• del 11 (q23;q25) • 1
• hypotetraploidy • 1
• t (16;16) (q22;24) • 1
• inv (9) • 1
• 46,XXY • 1
• +1, +2, +3, +5, del6, +7, +11, +12, -14, +22 • 1
• add (2), -3, -5, add (6), -7, -13, -16, -5, der6, t (6;10), -10, -13 • 1
• +8 • 1
• del20q • 1
• der19,t (1;19) • 1
RAEB-II 17 7 (41) 10 (58.8) • +8 • 4
• Hypotetraploidy (88~91) • 1
• Inv8, hyperdiploidy • 1
• -Y • 1
• +8, +21 • 1
• Del7 • 1
• Del5, del11 • 1
RAEB-I 8 4 (50) 4 (50) • del 7 • 1
• Complex 5q del • 1
• +8 • 1
• add (11), add (18), der11, t (1;11) • 1
RA 6 4 (66) 2 (33) • -Y • 1
• +8 • 1
RARS 2 2 (100) 0
RCMD-RS 1 1 (100) 0
Total 71 41 30
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Trisomy 8 has been identified by IPSS as an interme-
diate risk factor which is associated with poor survival,6
hence, such patients can be offered allogenic bone
marrow transplant as an upfront treatment modality.
Though advances have been made in determining the
molecular defects including FLT-3 and JAK2 mutation,
the importance of cytogenetic studies, still holds the
position in IPSS and WPSS in developing countries.
Although cytogenetic investigations in Pakistan are
performed in only a few hospitals at present, prospective
studies on a large number of patients are warranted to
elucidate more precisely the demographic and ethnic
differences in the pathogenesis of MDS amongst the
Pakistani population.
CONCLUSION
Trisomy 8 was the most common disorder/abnormality
found in this study population followed by the complex
cytogenetics.
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